Alnylam Pharma (DUL) Q1 2022 Earnings Report
4 Followers
DE:DUL Q1 2022 EPS Results
- Actual EPS
- -EUR 1.78
- Consensus EPS
- -EUR 1.61
- Beat/Miss
- Missed by -EUR 0.17
- One Year Ago EPS
- -EUR 1.52
DE:DUL Q1 2022 Revenue Results
- Actual Revenue
- EUR 189.49M
- Expected Revenue
- EUR 214.09M
- Beat/Miss
- Missed by -EUR 24.60M
- YoY Revenue Growth
- +20.10%
Earnings Announcement Details
- Quarter
- Q1 2022
- Date
- 04/28/2022
- Time
- Before Open
- Conference Call
- Thursday, April 28, 2022
DE:DUL Upcoming Earnings
Alnylam Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q1 2022 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q1 2022 Earnings Slide Deck
No slide deck is available for this earnings event.
Q1 2022 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:DUL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 1.53- | 0.73 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.4713.97 | 1.63 | 754.35% (+12.33) | |
| Jul 30, 2026 | 2026 (Q2) | 1.451.08 | -0.45 | 337.25% (+1.53) | |
| Apr 30, 2026 | 2026 (Q1) | 0.771.34 | -0.39 | 443.18% (+1.73) | |
| Feb 12, 2026 | 2025 (Q4) | 1.020.73 | -0.58 | 226.15% (+1.31) | |
| Oct 30, 2025 | 2025 (Q3) | 0.501.63 | -0.77 | 311.49% (+2.41) | |
| Jul 31, 2025 | 2025 (Q2) | -0.48-0.45 | -0.12 | -292.31% (-0.34) | |
| May 01, 2025 | 2025 (Q1) | -0.79-0.39 | -0.46 | 15.38% (+0.07) | |
| Feb 13, 2025 | 2024 (Q4) | -0.53-0.58 | -0.98 | 40.91% (+0.40) | |
| Oct 31, 2024 | 2024 (Q3) | -0.81-0.77 | 1.02 | -175.65% (-1.79) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
